SOCRA CCRP EXAM ACTUAL EXAM 100+ QUESTIONS
AND CORRECT DETAILED ANSWERS WITH
RATIONALES |AGRADE|VERIFIED
/April 30 1996 - Answer-ICH GCP Development Date
/.Quality - Answer-ICH Q
/.Efficacy - Answer-ICH E
/.Safety - Answer-ICH S
/.Multidisciplinary - Answer-ICH M
/.guidance for industry, consolidated guideance - Answer-ICH E 6
/.Clinical Safety Data Management Definitions and Standards - Answer-ICH E2A
/.Safety pharmacology studies for human pharmaceuticals - Answer-ICH S7A
/.Electronic records, electronic signatures - Answer-21 CFR Part 11
/.Informed Consent - Answer-21 CFR Part 50
/.Financial Disclosures - Answer-21 CFR Part 54
/.Institutional Review Board - Answer-21 CFR Part 56
/.IND Application - Answer-21 CFR 312
/.New Drug Application - Answer-21 CFR 314
/.Investigational Device Exemption - Answer-21 CFR 812
/.21 CFR Part 814 - Answer-pre market approval of medical devices
/.45 CFR Part 46 - Answer-Federal Research
/.Studies that investigate the potential undesirable PD effects of a substance on
physiological functions in relation to exposure in the therapeutic range or above -
Answer-Safety Pharmacology Studies (Pre-Clinical)
,/.1) To Identify undesirable PD properties of a substance that may have relevance to its
human safety.
2) To evaluate adverse PD and/or pathophysio effects of a substance observed in
toxicology studies
3)to investigate the mechanism of the adverse PD effects observed and/or suspected -
Answer-Drug Development Safety Pharmacology Study Objectives (3)
/.1) Cardiovascular
2)Respiratory
3)CNS - Answer-Three vital organ considered highest priority
/.1) PK and toxicokinetic
2) Single dose toxicity
3) Repeated dose toxicity
4) Local tolerance
5) Genotoxicity
6) Carcinogenicity
7) Reproduction toxicity
8) Supplemental studies if needed - Answer-Types of Non-Clinical Studies (Animal
Trials)
/.Study that investigates the mode of action and/or effects of a drug substance in
relation to its desired therapeutic target - Answer-Primary Pharmacodynamic Studies
/.Studies that investigate the mode of action and/or effects of a drug substance not
related to its desire therapeutic target - Answer-Secondary Pharmacodynamic Studies
/.Blood Pressure
Heart Rate
ECG/EKG
Repolarization/conductance abnormalities - Answer-Core Battery for Cardiovascular
System
/.Respiratory Rate
Functional Assessments (tidal volume, hgb Oxygen saturation) - Answer-Core Battery
for Respiratory System
/.Motor activity
behavioral changes
coordination
sensory/motor reflex response
temperature - Answer-Core Battery for Central Nervous System
/.Investigational New Drug Application
, FDA - Answer-Before clinical trials can be initiated, an application containing the
appropriate information must be submitted to regulatory authorities, in the USA this is
called XXXX and submitted to the XXX (21 CFR Part 312)
/.Unapproved drug to be shipped lawfully for the purpose of conducting investigations of
the drug - Answer-An IND permits what? (21 CFR Part 312)
/.Assuring the safety and rights of subjects - Answer-FDA's primary objective in all
phases of development is...
/.Phase II and III - Answer-These phase of trials, the FDA helps assure the quality of the
scientific evaluation is adequate to permit evaluation of the drugs safety and efficacy (21
CFR Part 312)
/.The FDA - Answer-Who determines if Phase II/III studies are likely to yield data
capable of meeting regulatory standards for marketing approval?
/.1) Novelty of drug
2)Extent the drug has been studied previously
3) Known of suspected risks
4) Phase of development - Answer-IND information depends on the amount of
information available, these 4 things are: (21 CFR Part 312)
/.General Investigational Plan
Protocols for specific human studies - Answer-Initial IND should focus on (21 CFR Part
312)
/.Build logically on previous submissions
Be supported by additional information such as animal studies and other human studies
- Answer-Amendments to IND with new or revised protocols (21 CFR Part 312)
/.Cover Sheet (FDA Form 1571)
Table of Contents
Introductory statement
investigator's brochure
protocol (s)
Chemistry and manufacturing information
pharm and tox information
previous human experience with investigational drug - Answer-A Sponsor Initiated IND
must contain (21 CFR Part 312)
/.30 Days, unless FDA notifies sponsor of clinical hold
Upon earlier notification, investigations may begin - Answer-How long does it take for an
IND to go into effect? (21 CFR Part 312)
AND CORRECT DETAILED ANSWERS WITH
RATIONALES |AGRADE|VERIFIED
/April 30 1996 - Answer-ICH GCP Development Date
/.Quality - Answer-ICH Q
/.Efficacy - Answer-ICH E
/.Safety - Answer-ICH S
/.Multidisciplinary - Answer-ICH M
/.guidance for industry, consolidated guideance - Answer-ICH E 6
/.Clinical Safety Data Management Definitions and Standards - Answer-ICH E2A
/.Safety pharmacology studies for human pharmaceuticals - Answer-ICH S7A
/.Electronic records, electronic signatures - Answer-21 CFR Part 11
/.Informed Consent - Answer-21 CFR Part 50
/.Financial Disclosures - Answer-21 CFR Part 54
/.Institutional Review Board - Answer-21 CFR Part 56
/.IND Application - Answer-21 CFR 312
/.New Drug Application - Answer-21 CFR 314
/.Investigational Device Exemption - Answer-21 CFR 812
/.21 CFR Part 814 - Answer-pre market approval of medical devices
/.45 CFR Part 46 - Answer-Federal Research
/.Studies that investigate the potential undesirable PD effects of a substance on
physiological functions in relation to exposure in the therapeutic range or above -
Answer-Safety Pharmacology Studies (Pre-Clinical)
,/.1) To Identify undesirable PD properties of a substance that may have relevance to its
human safety.
2) To evaluate adverse PD and/or pathophysio effects of a substance observed in
toxicology studies
3)to investigate the mechanism of the adverse PD effects observed and/or suspected -
Answer-Drug Development Safety Pharmacology Study Objectives (3)
/.1) Cardiovascular
2)Respiratory
3)CNS - Answer-Three vital organ considered highest priority
/.1) PK and toxicokinetic
2) Single dose toxicity
3) Repeated dose toxicity
4) Local tolerance
5) Genotoxicity
6) Carcinogenicity
7) Reproduction toxicity
8) Supplemental studies if needed - Answer-Types of Non-Clinical Studies (Animal
Trials)
/.Study that investigates the mode of action and/or effects of a drug substance in
relation to its desired therapeutic target - Answer-Primary Pharmacodynamic Studies
/.Studies that investigate the mode of action and/or effects of a drug substance not
related to its desire therapeutic target - Answer-Secondary Pharmacodynamic Studies
/.Blood Pressure
Heart Rate
ECG/EKG
Repolarization/conductance abnormalities - Answer-Core Battery for Cardiovascular
System
/.Respiratory Rate
Functional Assessments (tidal volume, hgb Oxygen saturation) - Answer-Core Battery
for Respiratory System
/.Motor activity
behavioral changes
coordination
sensory/motor reflex response
temperature - Answer-Core Battery for Central Nervous System
/.Investigational New Drug Application
, FDA - Answer-Before clinical trials can be initiated, an application containing the
appropriate information must be submitted to regulatory authorities, in the USA this is
called XXXX and submitted to the XXX (21 CFR Part 312)
/.Unapproved drug to be shipped lawfully for the purpose of conducting investigations of
the drug - Answer-An IND permits what? (21 CFR Part 312)
/.Assuring the safety and rights of subjects - Answer-FDA's primary objective in all
phases of development is...
/.Phase II and III - Answer-These phase of trials, the FDA helps assure the quality of the
scientific evaluation is adequate to permit evaluation of the drugs safety and efficacy (21
CFR Part 312)
/.The FDA - Answer-Who determines if Phase II/III studies are likely to yield data
capable of meeting regulatory standards for marketing approval?
/.1) Novelty of drug
2)Extent the drug has been studied previously
3) Known of suspected risks
4) Phase of development - Answer-IND information depends on the amount of
information available, these 4 things are: (21 CFR Part 312)
/.General Investigational Plan
Protocols for specific human studies - Answer-Initial IND should focus on (21 CFR Part
312)
/.Build logically on previous submissions
Be supported by additional information such as animal studies and other human studies
- Answer-Amendments to IND with new or revised protocols (21 CFR Part 312)
/.Cover Sheet (FDA Form 1571)
Table of Contents
Introductory statement
investigator's brochure
protocol (s)
Chemistry and manufacturing information
pharm and tox information
previous human experience with investigational drug - Answer-A Sponsor Initiated IND
must contain (21 CFR Part 312)
/.30 Days, unless FDA notifies sponsor of clinical hold
Upon earlier notification, investigations may begin - Answer-How long does it take for an
IND to go into effect? (21 CFR Part 312)
